A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

Trial Profile

A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Typhoid vaccine Vi DT conjugate International Vaccine Institute/Incepta/SK Chemicals/PT Biofarma (Primary) ; Influenza virus vaccine; Pneumococcal vaccine conjugate; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Adverse reactions
  • Sponsors PT Bio Farma
  • Most Recent Events

    • 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 12 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top